From: Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months
Patients (n)
8
Age (years)
47.0 ± 9.7
Sex ratio (M/F)
5/3
Smokers/nonsmokers
1/7
Body mass index
23.8 ± 3.1
Total plasma IgE (kU/L)
309.4 ± 218.2
Forced expiratory volume in the first second
52% pred ± 14%
Asthma control test score
11.3 ± 2.8